» Articles » PMID: 35909511

Human Immunocompetent Model of Neuroendocrine Liver Metastases Recapitulates Patient-Specific Tumour Microenvironment

Abstract

Neuroendocrine liver metastases (LM-NEN) develop in a considerable proportion of patients with gastroenteropancreatic neuroendocrine neoplasms. There is a paucity of experimental models that accurately recapitulate this complex metastatic human liver microenvironment precluding scientific and clinical advancements. Here, we describe the development of a novel personalised immunocompetent precision cut tumour slice (PCTS) model for LM-NEN using resected human liver tissue. The histological assessment throughout the culture demonstrated that slices maintain viability for at least 7 days and retain the cellular heterogeneity of the original tumour. Essential clinical features, such as patient-specific histoarchitecture, tumour grade, neuroendocrine differentiation and metabolic capacity, are preserved in the slices. The PCTS also replicate the tumor-specific immunological profile as shown by the innate and adaptive immunity markers analysis. Furthermore, the study of soluble immune checkpoint receptors in the culture supernatants proves that these immunomodulators are actively produced by LM-NEN and suggests that this process is epithelium-dependent. This model can be employed to investigate these pathways and provides a powerful platform for mechanistic, immunological and pre-clinical studies.

Citing Articles

Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges.

Cigliano A, Liao W, Deiana G, Rizzo D, Chen X, Calvisi D Biomedicines. 2024; 12(7).

PMID: 39062197 PMC: 11274649. DOI: 10.3390/biomedicines12071624.


Alcohol-Associated Liver Disease Outcomes: Critical Mechanisms of Liver Injury Progression.

Osna N, Tikhanovich I, Ortega-Ribera M, Mueller S, Zheng C, Mueller J Biomolecules. 2024; 14(4.

PMID: 38672422 PMC: 11048648. DOI: 10.3390/biom14040404.


Human Precision-Cut Liver Slices: A Potential Platform to Study Alcohol-Related Liver Disease.

Rastovic U, Bozzano S, Riva A, Simoni-Nieves A, Harris N, Miquel R Int J Mol Sci. 2024; 25(1).

PMID: 38203321 PMC: 10778645. DOI: 10.3390/ijms25010150.


Breast Cancer Tissue Explants: An Approach to Develop Personalized Therapy in Public Health Services.

Carranza-Rosales P, Valencia-Mercado D, Esquivel-Hernandez O, Gonzalez-Geroniz M, Banuelos-Garcia J, Castruita-Avila A J Pers Med. 2023; 13(10).

PMID: 37888132 PMC: 10608341. DOI: 10.3390/jpm13101521.


Patient-derived precision cut tissue slices from primary liver cancer as a potential platform for preclinical drug testing.

Jagatia R, Doornebal E, Rastovic U, Harris N, Feyide M, Lyons A EBioMedicine. 2023; 97:104826.

PMID: 37806285 PMC: 10667128. DOI: 10.1016/j.ebiom.2023.104826.

References
1.
Modlin I, Moss S, Chung D, Jensen R, Snyderwine E . Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008; 100(18):1282-9. PMC: 2538549. DOI: 10.1093/jnci/djn275. View

2.
Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

3.
Van Buren 2nd G, Rashid A, Yang A, Abdalla E, Gray M, Liu W . The development and characterization of a human midgut carcinoid cell line. Clin Cancer Res. 2007; 13(16):4704-12. DOI: 10.1158/1078-0432.CCR-06-2723. View

4.
Kim S, Ha S, Lee S, Ahn S, Lee J, Park S . The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. J Cancer. 2016; 7(5):484-9. PMC: 4780123. DOI: 10.7150/jca.13711. View

5.
Basuroy R, Srirajaskanthan R, Ramage J . A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol. 2012; 2012:819193. PMC: 3296190. DOI: 10.1155/2012/819193. View